デフォルト表紙
市場調査レポート
商品コード
1409197

鎮痙薬の世界市場レポート 2024年

Antispasmodics Drugs Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
鎮痙薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

鎮痙薬市場規模は近年力強く成長しています。2023年の126億9,000万米ドルから2024年には139億2,000万米ドルに、CAGR9.7%で成長します。抗痙攣薬の分野で歴史的な期間に観察された成長は、いくつかの要因に起因しています。これらには、痙攣に関連する疾患の有病率の増加、より良い理解と治療法の選択肢につながる医学研究の進歩、関連する医療ニーズを伴う高齢化人口の増加、健康状態に影響を与えるライフスタイルの変化、診断能力の向上などが含まれます。これらの要因が総体的に、歴史的な期間における鎮痙薬の需要と発展に寄与しています。

2023年の鎮痙薬市場では北米が最大地域でした。アジア太平洋は、鎮痙薬市場レポートにおいて予測期間中に最も急成長する地域となる見込みです。当レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 鎮痙薬市場の特徴

第3章 鎮痙薬市場の動向と戦略

第4章 鎮痙薬市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の鎮痙薬市場の規模と成長

  • 世界の鎮痙薬市場の促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界の鎮痙薬市場規模の実績と成長率、2018-2023
  • 世界の鎮痙薬市場規模と成長予測、2023-2028、2033年

第6章 鎮痙薬市場セグメンテーション

  • 世界の鎮痙薬市場、薬剤別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
    • ジシクロミン塩酸塩
    • ロペラミド塩酸塩
    • その他の薬物
  • 世界の鎮痙薬市場、適応症別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
    • 過敏性腸症候群
    • 胃のけいれん
    • その他の適応症
  • 世界の鎮痙薬市場、投与経路別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
    • オーラル
    • 非オーラル
    • 他の投与方法
  • 世界の鎮痙薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • 世界の鎮痙薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
    • 病院
    • ホームケア
    • 専門クリニック
    • その他のエンドユーザー

第7章 鎮痙薬市場の地域および国分析

  • 世界の鎮痙薬市場、地域別、実績および予測、2018-2023、2023-2028、2033年
  • 世界の鎮痙薬市場、国別、実績および予測、2018-2023、2023-2028、2033年

第8章 アジア太平洋の鎮痙薬市場

第9章 中国の鎮痙薬市場

第10章 インドの鎮痙薬市場

第11章 日本の鎮痙薬市場

第12章 オーストラリアの鎮痙薬市場

第13章 インドネシアの鎮痙薬市場

第14章 韓国の鎮痙薬市場

第15章 西欧の鎮痙薬市場

第16章 英国の鎮痙薬市場

第17章 ドイツの鎮痙薬市場

第18章 フランスの鎮痙薬市場

第19章 イタリアの鎮痙薬市場

第20章 スペインの鎮痙薬市場

第21章 東欧の鎮痙薬市場

第22章 ロシアの鎮痙薬市場

第23章 北米の鎮痙薬市場

第24章 米国の鎮痙薬市場

第25章 カナダの鎮痙薬市場

第26章 南米の鎮痙薬市場

第27章 ブラジルの鎮痙薬市場

第28章 中東の鎮痙薬市場

第29章 アフリカの鎮痙薬市場

第30章 鎮痙薬市場の競合情勢と企業プロファイル

  • 鎮痙薬市場の競合情勢
  • 鎮痙薬市場の企業プロファイル
    • Daiichi Sankyo Company Limited
    • Fresenius Kabi AG
    • Hikma Pharmaceuticals plc
    • Johnson &Johnson Services Inc.
    • Pfizer Inc.

第31章 世界の抗けいれん薬市場の競合ベンチマーキング

第32章 世界の抗けいれん薬市場の競争ダッシュボード

第33章 鎮痙薬市場における主要な合併と買収

第34章 鎮痙薬市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r10735

“Antispasmodics Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antispasmodics drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antispasmodics drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The antispasmodics drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug: Dicyclomine Hydrochloride; Loperamide Hydrochloride; Other Drugs
  • 2) By Indication: Irritable Bowel Syndrome; Stomach Cramps; Other Indications
  • 3) By Route Of Administration: Oral; Parenteral; Other Modes Of Administrations
  • 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
  • Companies Mentioned: Daiichi Sankyo Company Limited; Fresenius Kabi AG; Hikma Pharmaceuticals plc; Johnson & Johnson Services Inc.; Pfizer Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Antispasmodic drugs are medications designed to treat, prevent, or decrease the frequency of muscular spasms, especially those involving smooth muscle, such as those occurring in the walls of the gastrointestinal tract. These drugs function by slowing down the normal movements of the gut and inducing relaxation in the muscles of the stomach and intestines.

Key drugs in the category of antispasmodics include dicyclomine hydrochloride, loperamide hydrochloride, and others. Dicyclomine is an anticholinergic medication that reduces spasms in the gastrointestinal muscles by inhibiting the activity of a natural chemical in the body. Indications for the use of antispasmodic drugs include conditions such as irritable bowel syndrome, stomach cramps, and others. These medications can be administered through oral, parenteral, and other modes. Distribution channels for antispasmodic drugs include hospital pharmacies, online pharmacies, and retail pharmacies, with end-users ranging from hospitals and homecare settings to specialty clinics and others.

The antispasmodics drugs market research report is one of a series of new reports from The Business Research Company that provides antispasmodics drugs market statistics, including antispasmodics drugs industry global market size, regional shares, competitors with antispasmodics drugs market share, detailed antispasmodics drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the antispasmodics drugs industry. This antispasmodic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antispasmodics drugs market size has grown strongly in recent years. It will grow from $12.69 billion in 2023 to $13.92 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth observed during the historical period in the field of antispasmodic drugs can be attributed to several factors. These include the increasing prevalence of conditions associated with spasms, advancements in medical research leading to better understanding and treatment options, a growing aging population with associated healthcare needs, changes in lifestyles impacting health conditions, and improvements in diagnostic capabilities. These factors collectively contributed to the demand and development of antispasmodic drugs during the historic period.

The antispasmodics drugs market size is expected to see strong growth in the next few years. It will grow to $20.04 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The anticipated growth in the forecast period in the field of antispasmodic drugs can be attributed to several factors. These include the increasing expenditure on healthcare, the trend towards personalized medicine, global population growth leading to higher healthcare demands, the emergence of new markets for pharmaceuticals, and ongoing clinical trials and research in the field. Major trends expected in the forecast period encompass the expansion of indications for antispasmodics, ongoing development of healthcare infrastructure, advancements in drug development processes, increasing awareness and diagnosis of spasmodic conditions, and a growing preference for non-invasive treatment options. These trends collectively contribute to the continued evolution and growth of the antispasmodic drugs market.

The anticipated rise in the elderly population stands as a driving force behind the growth of the antispasmodic drug market. Individuals aged 65 and above, often grappling with various physical and psychological health challenges, find relief in antispasmodic drugs to manage symptoms linked to conditions causing muscle spasms or cramping. These drugs also prove beneficial for ailments such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. In October 2022, the World Health Organization (WHO) projected a substantial increase in the global population aged 60 and above, expected to reach 1.4 billion by 2030 and double to 2.1 billion by 2050. This demographic shift, including a significant rise in those aged 80 or older, estimated to reach 426 million by 2050, underscores the impetus driving the antispasmodic drug market linked to an expanding elderly populace.

The burgeoning prevalence of irritable bowel syndrome (IBS) is poised to fuel the growth of the antispasmodic drugs market. IBS, a prevalent digestive disorder impacting the colon and causing discomfort and disruptions in digestive functionality, spurs the use of antispasmodics drugs. These medications target and alleviate muscle spasms and cramps within the gastrointestinal tract, providing relief from abdominal pain and discomfort associated with IBS. For example, statistics from The Public Health Agency of Canada in July 2021 revealed approximately 260,000 Canadians affected by Inflammatory Bowel Disease (IBD), commonly identified in adults in their twenties and older teens. This escalation in the prevalence of IBS underscores the driving force behind the expansion of the antispasmodic drugs market, addressing the growing need for effective remedies catering to digestive health.

Innovative product developments emerge as a pivotal trend fueling the ascent of the antispasmodic drugs market. Key players in this domain prioritize pioneering solutions to fortify their market positions. For instance, in April 2022, Ardelyx Inc., a US-based biopharmaceutical company, unveiled IBSRELA, an NHE-3 inhibitor tailored for individuals grappling with irritable bowel syndrome with constipation (IBS-C). This product represents a breakthrough therapeutic option boasting a novel mode of action, yielding significant efficacy in addressing constipation and assorted abdominal symptoms prevalent in IBS-C patients, as substantiated by Phase 3 clinical studies. This innovative approach underscores the market's trend towards developing impactful solutions catering to specific conditions within the antispasmodic drugs segment.

Prominent entities within the antispasmodics drugs market are unveiling new products as part of their strategy to fortify their market presence. For example, in January 2023, Lupin Limited, an India-based pharmaceutical company, introduced Fesoterodine Fumarate, an FDA-approved generic antispasmodic drug. This medication is specifically designed to address certain bladder issues such as overactive bladder and neurogenic detrusor overactivity. Belonging to the antispasmodic drug class, Fesoterodine Fumarate functions by relaxing the muscles in the bladder. It is available in extended-release tablet form, representing a new addition to Lupin Limited's repertoire in addressing bladder-related ailments.

In October 2022, Silo Wellness Inc., a US-based company specializing in psychedelic therapy, concluded the acquisition of Dyscovry Science Ltd. for an undisclosed amount. This strategic acquisition enables Silo Wellness to consolidate its presence in the psychedelic business landscape. Dyscovry Science Ltd., a Canada-based biotechnology firm, specializes in biosynthetic production of psilocybin and its derivatives for treating irritable bowel syndrome. By incorporating Dyscovry Science Ltd., Silo Wellness aims to encompass both facets of the psychedelic industry, augmenting its capabilities in research and biosynthetic development for innovative treatment solutions.

Major companies operating in the antispasmodics drugs market report are Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Pfizer Inc., Shanghai Fosun Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Akorn Inc., Aurobindo Pharma Limited, Lannett Company Inc., Nexus Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Blue Cross Laboratories Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Lexicare Pharma Pvt. Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Wellona Pharma Private Limited, SunGen Pharma LLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Ltd. .

North America was the largest region in the antispasmodics drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the antispasmodics drugs market report during the forecast period. The regions covered in the antispasmodics drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antispasmodics drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antispasmodics drugs market consists of sales of natural alkaloids such as atropine, belladonna, hyoscyamine, scopolamine, and related drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Antispasmodics Drugs Market Characteristics

3. Antispasmodics Drugs Market Trends And Strategies

4. Antispasmodics Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Antispasmodics Drugs Market Size and Growth

  • 5.1. Global Antispasmodics Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Antispasmodics Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Antispasmodics Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antispasmodics Drugs Market Segmentation

  • 6.1. Global Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Dicyclomine Hydrochloride
  • Loperamide Hydrochloride
  • Other Drugs
  • 6.2. Global Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Irritable Bowel Syndrome
  • Stomach Cramps
  • Other Indications
  • 6.3. Global Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Other Modes Of Administrations
  • 6.4. Global Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmnacy
  • 6.5. Global Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End-Users

7. Antispasmodics Drugs Market Regional And Country Analysis

  • 7.1. Global Antispasmodics Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Antispasmodics Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antispasmodics Drugs Market

  • 8.1. Asia-Pacific Antispasmodics Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antispasmodics Drugs Market

  • 9.1. China Antispasmodics Drugs Market Overview
  • 9.2. China Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antispasmodics Drugs Market

  • 10.1. India Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antispasmodics Drugs Market

  • 11.1. Japan Antispasmodics Drugs Market Overview
  • 11.2. Japan Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antispasmodics Drugs Market

  • 12.1. Australia Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antispasmodics Drugs Market

  • 13.1. Indonesia Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antispasmodics Drugs Market

  • 14.1. South Korea Antispasmodics Drugs Market Overview
  • 14.2. South Korea Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antispasmodics Drugs Market

  • 15.1. Western Europe Antispasmodics Drugs Market Overview
  • 15.2. Western Europe Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antispasmodics Drugs Market

  • 16.1. UK Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antispasmodics Drugs Market

  • 17.1. Germany Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antispasmodics Drugs Market

  • 18.1. France Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antispasmodics Drugs Market

  • 19.1. Italy Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antispasmodics Drugs Market

  • 20.1. Spain Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antispasmodics Drugs Market

  • 21.1. Eastern Europe Antispasmodics Drugs Market Overview
  • 21.2. Eastern Europe Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antispasmodics Drugs Market

  • 22.1. Russia Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antispasmodics Drugs Market

  • 23.1. North America Antispasmodics Drugs Market Overview
  • 23.2. North America Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antispasmodics Drugs Market

  • 24.1. USA Antispasmodics Drugs Market Overview
  • 24.2. USA Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antispasmodics Drugs Market

  • 25.1. Canada Antispasmodics Drugs Market Overview
  • 25.2. Canada Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antispasmodics Drugs Market

  • 26.1. South America Antispasmodics Drugs Market Overview
  • 26.2. South America Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antispasmodics Drugs Market

  • 27.1. Brazil Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antispasmodics Drugs Market

  • 28.1. Middle East Antispasmodics Drugs Market Overview
  • 28.2. Middle East Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antispasmodics Drugs Market

  • 29.1. Africa Antispasmodics Drugs Market Overview
  • 29.2. Africa Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antispasmodics Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Antispasmodics Drugs Market Competitive Landscape
  • 30.2. Antispasmodics Drugs Market Company Profiles
    • 30.2.1. Daiichi Sankyo Company Limited
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Fresenius Kabi AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Hikma Pharmaceuticals plc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Johnson & Johnson Services Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Pfizer Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Antispasmodics Drugs Market Competitive Benchmarking

32. Global Antispasmodics Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Antispasmodics Drugs Market

34. Antispasmodics Drugs Market Future Outlook and Potential Analysis

  • 34.1 Antispasmodics Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Antispasmodics Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Antispasmodics Drugs Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer